An interventional study of Anterior Cervical Discectomy and Fusion in Cervical Degenerative Disc Disease, sponsored by Synergy Spine Solutions. Active, not recruiting at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Synergy Spine Solutions · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.
Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 28th largest by planned enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2023, is one of 90 with no phase, reaches primary completion later than 22 of the 57 other live ones, and was the 203rd registered.
462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.
Browse Intervertebral Disc Degeneration studies →41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
CGBio Inc. · Sites in United States
Ages 21–80
EicOsis Human Health Inc. · Sites in United States
Ages 18+
DiscGenics, Inc. · Sites in United States
Ages 18–75
VIVEX Biologics, Inc. · Sites in United States
Ages 22–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 20 · Phase 3 18 · Phase 4 8
First in 1998; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 60 across 256 interventional studies indexed under Intervertebral Disc Degeneration.
Median enrollment 57 across the 141 interventional studies, 118 across the 91 observational. Of the 132 that completed or were terminated, 44 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
165 of 232 have an industry lead sponsor. The 10 most frequent:
Synergy Spine Solutions is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Synergy Spine Solutions has 4 studies filed under Intervertebral Disc Degeneration — fewer than ten, so there is no comparison to draw.
17 of the studies in Intervertebral Disc Degeneration with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06325566Phase 3Mesoblast, Ltd.Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain | 2027-07 |
| NCT07254806Phase 3DiscGenics, Inc.A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease | 2027-11-24 |
| NCT05740176Synergy Spine SolutionsThe Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery | 2026-11 |
| NCT05037968Kuros Biosurgery AGMagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion | 2026-12 |
| NCT04388332Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)ACDF Using Structural Allograft vs. Tritanium C | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multicenter, prospective, non-randomized, historically controlled study. To demonstrate the Synergy Disc is at least as safe and effective as conventional anterior cervical discectomy and fusion (ACDF) to treat cervical degenerative disc disease (DDD) in subjects who are symptomatic at two levels from C3 to C7 are and are unresponsive to conservative management. Patients will be evaluated preoperatively, at the time of surgery, and at 6 weeks, and 3, 6, 12, and 24 months after surgery. Follow-up will continue annually until the last patient reaches 24-month follow-up. The primary analysis will occur at 24 months.
This is a research study comparing two ways of treating neck problems caused by degenerative disc disease (wear-and-tear damage to the discs that cushion the bones in the neck).
The study is comparing:
The Synergy Disc - an artificial disc device being studied in this trial, and Standard surgery (ACDF) - a widely used procedure called anterior cervical discectomy and fusion, which is the accepted current treatment.
Up to 200 people will receive the Synergy Disc as part of this study. Their results will be compared to results from people who had the standard ACDF surgery in the past, rather than assigning some people to get ACDF during this study (this is called a "historical control"). The study takes place at multiple medical centers.
Who this study is for:
People who are fully grown (skeletally mature) and have damage in two neighboring discs in the neck (located somewhere between the C3 and C7 vertebrae). To qualify, a person's symptoms must include:
Arm pain and/or nerve-related weakness or numbness (radiculopathy) that hasn't improved, and Neck pain or signs of spinal cord compression (myelopathy)
These symptoms must be caused by problems in the two affected disc levels, and must not have gotten better with non-surgical treatment (such as physical therapy, medication, or injections).
What the study will measure:
Whether the Synergy Disc is as safe and effective as standard ACDF surgery for people who need surgery to relieve pressure on the nerves or spinal cord at two neighboring disc levels in the neck.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, subjects must meet all of the following criteria:
Exclusion Criteria:
Subjects who meet any of the following criteria will be excluded from participation in this study:
Has documented or diagnosed cervical instability relative to adjacent segments at either level, defined by dynamic (flexion/extension) radiographs showing:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Synergy Disc is a cervical disc prosthesis that can be inserted between C3-C7 in skeletally mature patients after anterior discectomy to provide restoration of motion to the functional spinal unit. The Synergy Disc is designed to restore kinematics to the cervical spine. The Synergy Disc is intended for use in the cervical spine for reconstruction of the disc following a two level discectomy for intractable radiculopathy and/or myelopathy.
Device: Anterior Cervical Discectomy and Fusion
Anterior cervical discectomy is a surgical procedure that was developed to treat damaged cervical discs by relieving pressure on the nerve roots or on the spinal cord by removing the ruptured disc. The operation is performed by reaching the cervical spine through a small incision in the front of the neck. The soft tissues of the neck are then separated allowing for the disc to be removed. Anterior cervical discectomy has proven to be a safe and effective procedure for the treatment of degenerative disc disease. The anterior approach allows direct visualization of the entire interspace and wide decompression of the anterior aspect cervical spinal cord and nerve roots. It may be undertaken in cases of multilevel disease and interbody fusion may be performed if required
Also known as: ACDF
NDI
≥ 15-point improvement in NDI Score (out of 100) in subjects at 24 months compared with baseline
Time frame: 24 month
Standardized Neurological Assessment Scales
Maintenance or improvement in neurological status (motor and sensory only) at 24 months compared to baseline
Time frame: 24 month
Secondary Surgical Intervention
No study failure due to secondary surgical interventions (revision, removal, re-operation, supplemental fixation) at the index levels
Time frame: 24 month
Device Related Adverse Event
Absence of major device related adverse events defined as radiographic failure, neurological failure, or failure by adverse event as adjudicated by the CEC.
Time frame: 24 month
SF-36
Health Survey (SF-36) at baseline and at each follow-up time-point
Time frame: pre-operative, 6 week, 3 month, 6 month, 12 month, 24 month
VAS
Visual analogue scale (VAS) will be used to evaluate pain where a change of at least 20mm will be considered clinically significant. Neck pain as measured on a 100mm VAS at baseline and at each follow-up time-point. Left and Right arm/shoulder pain as measured on a 100mm VAS at baseline and at each follow-up time-point. Please note, this assessment will include a "Worst" to pool together the left or right arm/shoulder scores with the higher baseline score. VAS Hoarseness on a 100mm scale.
Time frame: pre-operative, 6 week, 3 month, 6 month, 12 month, 24 month
Patient Satisfaction
Patient Satisfaction Questionnaire
Time frame: 6 week, 3 month, 6 month, 12 month, 24 month
BZ Score
Bazaz Dysphagia Score at 24 months compared to baseline
Time frame: 6 week, 3 month, 6 month, 12 month, 24 month
Odom's Criteria
Results at 24 months for the investigational Synergy Disc and at 24 months for the control ACDF will also be categorized by the physician according to Odom's Criteria.
Time frame: 6 week, 3 month, 6 month, 12 month, 24 month
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Nov 2026, 41 months after the start.
Of 45 industry-sponsored interventional studies with no phase under Intervertebral Disc Degeneration, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 82. This study's planned 41 months is below that.
Counting every sponsor, half of 85 studies reached it within 50 months; a quarter within 27 and three quarters within 72.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intervertebral Disc Degeneration →
Synergy Spine Solutions